Atossa Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO Atossa Therapeutics is Steve Quay, benoemd in Apr2009, heeft een ambtstermijn van 15.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.36M, bestaande uit 30% salaris en 70% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.002% van de aandelen van het bedrijf, ter waarde $ 3.19K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 12.8 jaar.
Belangrijke informatie
Steve Quay
Algemeen directeur
US$2.4m
Totale compensatie
| Percentage CEO-salaris | 30.0% |
| Dienstverband CEO | 15.6yrs |
| Eigendom CEO | 0.002% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 12.8yrs |
Recente managementupdates
Recent updates
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Nov 12
Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go
Nov 08We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Jul 01Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Mar 07We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Nov 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Apr 26We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Jan 09Atossa Therapeutics: Still Gets An 'Incomplete' Rating
Oct 11We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
Sep 25Atossa Therapeutics GAAP EPS of -$0.05
Aug 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
May 12A First Assessment On Atossa Therapeutics
Dec 10We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 02Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World
Sep 22Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business
Jul 17Atossa Therapeutics: Hope Springs Eternal
Jun 30Atossa Therapeutics to be included in the Russell 2000, 3000 indexes
Jun 16Atossa reaches a two-year high ahead of data readout for breast cancer therapy
Jun 07Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Apr 02Atossa updates on single-patient study for Endoxifen
Feb 04Atossa halts Endoxifen breast cancer study after positive data
Feb 02Atossa Therapeutics prices ~$25M direct offering, stock -23% PM
Jan 06Atossa Therapeutics prices $14M registered direct offering
Dec 17We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 10
Atossa Therapeutics plummets 38% after it raises $20M in public offering
Dec 09Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$27m |
| Jun 30 2024 | n/a | n/a | -US$26m |
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$2m | US$706k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$32m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$3m | US$706k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$21m |
| Mar 31 2022 | n/a | n/a | -US$22m |
| Dec 31 2021 | US$6m | US$659k | -US$21m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$3m | US$601k | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | n/a | n/a | -US$13m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$6m | US$601k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$25m |
| Dec 31 2018 | US$2m | US$582k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$22m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$1m | US$520k | -US$11m |
Compensatie versus markt: De totale vergoeding ($USD 2.36M ) Steve } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.47M ).
Compensatie versus inkomsten: De vergoeding van Steve is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Steve Quay (73 yo)
15.6yrs
Tenure
US$2,356,220
Compensatie
Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 15.6yrs | US$2.36m | 0.0021% $ 3.2k | |
| Chief Financial Officer & Principal Accounting Officer | 3.8yrs | US$687.46k | 0% $ 0 | |
| Senior Vice President of Administration & HR | 10.3yrs | geen gegevens | geen gegevens | |
| Vice President of Investor & Public Relations | 2.8yrs | geen gegevens | geen gegevens | |
| Interim Chief Medical Officer | 2.1yrs | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
Ervaren management: Het managementteam van ATOS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 15.6yrs | US$2.36m | 0.0021% $ 3.2k | |
| Independent Director | 10.7yrs | US$146.17k | 0% $ 0 | |
| Independent Director | 12.8yrs | US$144.92k | 0.00020% $ 301.9 | |
| Director | 15.6yrs | US$116.17k | 0.018% $ 26.7k | |
| Independent Director | 13.3yrs | US$144.92k | 0.000080% $ 120.8 | |
| Independent Director | less than a year | US$93.98k | 0.020% $ 30.0k | |
| Independent Director | less than a year | geen gegevens | geen gegevens |
12.8yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ATOS zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.8 jaar).